We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adtalem Global Education Inc. (ATGE - Free Report) reported strong results for fourth-quarter fiscal 2022. The company’s earnings and revenue surpassed the Zacks Consensus Estimate and increased year over year on the back of the Walden acquisition and cost synergies.
Despite lingering macro challenges for the industry, the company provided solid fiscal 2023 guidance.
In this connection, Steve Beard, president and CEO of Adtalem, said, “We have been proactive and purposeful in transforming our portfolio. Today, Adtalem is comprised of high-quality assets with market-leading brands, an experienced management team and an attractive healthcare focus. We are poised to win in the markets in which we compete.”
Earnings & Revenues Discussion
Adjusted earnings of $1.31 per share topped the consensus mark of $1.28 by 2.3% and surged by 172.9% from 48 cents in the year-ago quarter.
Revenues of $361.2 million beat the consensus mark of $347 million by 4.1% and increased 61.6% year over year, driven by the Walden acquisition. For the fiscal fourth quarter, enrollment of total students fell 7.2% year over year to 77,665.
Adjusted operating income rose 174.7% from the prior-year quarter’s levels to $88.1 million. Adjusted operating margin expanded a whopping 1000 basis points to 24.4%. Adjusted EBITDA was $103.2 million, up 139.9% from the prior-year quarter’s levels. Adjusted EBITDA margin increased 930 bps to 28.6% year over year.
Segment Details
Chamberlain: Revenues in the segment fell 1.1% from the year-ago quarter’s figure to $140.2 million. Adjusted operating income increased 38.6% from the prior-year quarter’s levels to $41.7 million, primarily due to lower marketing and continued benefit from cost synergies. Adjusted EBITDA was $47.8 million, up 35.8% from the prior-year quarter’s levels.
Total student enrollment declined 5.8%, primarily owing to COVID-related headwinds in Chamberlain’s post-licensure programs, partially offset by improved enrollment and persistence in on-campus pre-licensure programs.
Walden: The segment generated revenues of $137.1 million. Total student enrollment in the quarter declined 9.5% year over year due to COVID-related headwinds in Walden’s post-licensure nursing programs and a decline in the management and technology programs. Adjusted operating income came in at $36.1 million. Adjusted EBITDA was $39.3 million.
Medical and Veterinary: Revenues in the segment increased 2.7% to $83.9 million from the year-ago quarter’s figure. Total student enrollment inched up 3.5% from the prior-year quarter’s levels, backed by growth in new student enrollment and higher persistence. Adjusted operating income increased 74.4% from the prior-year quarter’s figure to $19.6 million on increased revenue and the benefit from cost synergies. Adjusted EBITDA was $23.9 million, up 54.3% from the prior-year quarter’s levels.
Liquidity & Cash Flow
As of Jun 30, 2022, Adtalem had cash and cash equivalents of $346.97 million compared with $476.38 million at the fiscal 2021-end. Long-term debt was $838.9 million, up from $1.07 billion at the fiscal 2021-end.
For fiscal 2022, cash provided by operating activities totaled $10.4 million compared with $192.2 million in the year-ago period. Free cash flow in the quarter was $96.6 million compared with $31.8 million a year ago.
Fiscal 2022 Highlights
For fiscal 2022, the company reported adjusted earnings of $3.24 per share, up 40.3% year over year. Revenues were up 53% from a year ago to $1.39 billion. Adjusted operating and EBITDA margins expanded 230 bps and 160 bps year over year, respectively.
Fiscal 2023 Guidance
For fiscal 2023, Adtalem expects revenues within $1,380-$1,450 million. The company expects adjusted earnings per share within $3.95-$4.20.
APEI’s top and the bottom line lagged the Zacks Consensus Estimate and declined on a year-over-year basis.
Strategic Education, Inc. or SEI (STRA - Free Report) reported second-quarter 2022. Quarterly earnings and revenues missed their respective Zacks Consensus Estimate and declined on a year-over-year basis.
The downside was caused by lower contributions from all three segments of STRA.
Leggett & Platt, Incorporated (LEG - Free Report) reported decent results in second-quarter 2022, with earnings meeting the Zacks Consensus Estimate and net sales surpassing the same. Both the metrics increased on a year-over-year basis.
Solid raw material-related selling prices helped the company generate higher sales and earnings. Yet, LEG witnessed soft volumes and currency headwinds.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adtalem (ATGE) Q3 Earnings & Revenue Beat, Margins Rise Y/Y
Adtalem Global Education Inc. (ATGE - Free Report) reported strong results for fourth-quarter fiscal 2022. The company’s earnings and revenue surpassed the Zacks Consensus Estimate and increased year over year on the back of the Walden acquisition and cost synergies.
Despite lingering macro challenges for the industry, the company provided solid fiscal 2023 guidance.
In this connection, Steve Beard, president and CEO of Adtalem, said, “We have been proactive and purposeful in transforming our portfolio. Today, Adtalem is comprised of high-quality assets with market-leading brands, an experienced management team and an attractive healthcare focus. We are poised to win in the markets in which we compete.”
Earnings & Revenues Discussion
Adjusted earnings of $1.31 per share topped the consensus mark of $1.28 by 2.3% and surged by 172.9% from 48 cents in the year-ago quarter.
Revenues of $361.2 million beat the consensus mark of $347 million by 4.1% and increased 61.6% year over year, driven by the Walden acquisition. For the fiscal fourth quarter, enrollment of total students fell 7.2% year over year to 77,665.
Adjusted operating income rose 174.7% from the prior-year quarter’s levels to $88.1 million. Adjusted operating margin expanded a whopping 1000 basis points to 24.4%. Adjusted EBITDA was $103.2 million, up 139.9% from the prior-year quarter’s levels. Adjusted EBITDA margin increased 930 bps to 28.6% year over year.
Segment Details
Chamberlain: Revenues in the segment fell 1.1% from the year-ago quarter’s figure to $140.2 million. Adjusted operating income increased 38.6% from the prior-year quarter’s levels to $41.7 million, primarily due to lower marketing and continued benefit from cost synergies. Adjusted EBITDA was $47.8 million, up 35.8% from the prior-year quarter’s levels.
Total student enrollment declined 5.8%, primarily owing to COVID-related headwinds in Chamberlain’s post-licensure programs, partially offset by improved enrollment and persistence in on-campus pre-licensure programs.
Walden: The segment generated revenues of $137.1 million. Total student enrollment in the quarter declined 9.5% year over year due to COVID-related headwinds in Walden’s post-licensure nursing programs and a decline in the management and technology programs. Adjusted operating income came in at $36.1 million. Adjusted EBITDA was $39.3 million.
Medical and Veterinary: Revenues in the segment increased 2.7% to $83.9 million from the year-ago quarter’s figure. Total student enrollment inched up 3.5% from the prior-year quarter’s levels, backed by growth in new student enrollment and higher persistence. Adjusted operating income increased 74.4% from the prior-year quarter’s figure to $19.6 million on increased revenue and the benefit from cost synergies. Adjusted EBITDA was $23.9 million, up 54.3% from the prior-year quarter’s levels.
Liquidity & Cash Flow
As of Jun 30, 2022, Adtalem had cash and cash equivalents of $346.97 million compared with $476.38 million at the fiscal 2021-end. Long-term debt was $838.9 million, up from $1.07 billion at the fiscal 2021-end.
For fiscal 2022, cash provided by operating activities totaled $10.4 million compared with $192.2 million in the year-ago period. Free cash flow in the quarter was $96.6 million compared with $31.8 million a year ago.
Fiscal 2022 Highlights
For fiscal 2022, the company reported adjusted earnings of $3.24 per share, up 40.3% year over year. Revenues were up 53% from a year ago to $1.39 billion. Adjusted operating and EBITDA margins expanded 230 bps and 160 bps year over year, respectively.
Fiscal 2023 Guidance
For fiscal 2023, Adtalem expects revenues within $1,380-$1,450 million. The company expects adjusted earnings per share within $3.95-$4.20.
Zacks Rank
Adtalem currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A Look at Some Recent Consumer Discretionary Releases
American Public Education, Inc. (APEI - Free Report) reported lackluster results in second-quarter 2022.
APEI’s top and the bottom line lagged the Zacks Consensus Estimate and declined on a year-over-year basis.
Strategic Education, Inc. or SEI (STRA - Free Report) reported second-quarter 2022. Quarterly earnings and revenues missed their respective Zacks Consensus Estimate and declined on a year-over-year basis.
The downside was caused by lower contributions from all three segments of STRA.
Leggett & Platt, Incorporated (LEG - Free Report) reported decent results in second-quarter 2022, with earnings meeting the Zacks Consensus Estimate and net sales surpassing the same. Both the metrics increased on a year-over-year basis.
Solid raw material-related selling prices helped the company generate higher sales and earnings. Yet, LEG witnessed soft volumes and currency headwinds.